BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 15363464)

  • 1. FDG-PET in the clinical management of Hodgkin lymphoma.
    Hutchings M; Eigtved AI; Specht L
    Crit Rev Oncol Hematol; 2004 Oct; 52(1):19-32. PubMed ID: 15363464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Position emission tomography with or without computed tomography in the primary staging of Hodgkin's lymphoma.
    Hutchings M; Loft A; Hansen M; Pedersen LM; Berthelsen AK; Keiding S; D'Amore F; Boesen AM; Roemer L; Specht L
    Haematologica; 2006 Apr; 91(4):482-9. PubMed ID: 16585015
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of PET in lymphoma.
    Jhanwar YS; Straus DJ
    J Nucl Med; 2006 Aug; 47(8):1326-34. PubMed ID: 16883013
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Feasibility of [18F]FDG-PET and coregistered CT on clinical target volume definition of advanced non-small cell lung cancer.
    Messa C; Ceresoli GL; Rizzo G; Artioli D; Cattaneo M; Castellone P; Gregorc V; Picchio M; Landoni C; Fazio F
    Q J Nucl Med Mol Imaging; 2005 Sep; 49(3):259-66. PubMed ID: 16172572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of 18F-FDG positron emission tomography following allogeneic transplantation to guide adoptive immunotherapy with donor lymphocyte infusions.
    Hart DP; Avivi I; Thomson KJ; Peggs KS; Morris EC; Goldstone AH; Linch DC; Ell PJ; Bomanji JB; Mackinnon S
    Br J Haematol; 2005 Mar; 128(6):824-9. PubMed ID: 15755287
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PET/CT for the staging and follow-up of patients with malignancies.
    Poeppel TD; Krause BJ; Heusner TA; Boy C; Bockisch A; Antoch G
    Eur J Radiol; 2009 Jun; 70(3):382-92. PubMed ID: 19406595
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The role of whole body 2-[fluorine-18]-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in the management of unknown primary tumors].
    Wu ZJ; Zhang YX; Wei H; Jia Q
    Zhonghua Yi Xue Za Zhi; 2007 Aug; 87(32):2253-6. PubMed ID: 18001544
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PET/CT for therapy response assessment in lymphoma.
    Hutchings M; Barrington SF
    J Nucl Med; 2009 May; 50 Suppl 1():21S-30S. PubMed ID: 19380407
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease.
    Gallamini A; Rigacci L; Merli F; Nassi L; Bosi A; Capodanno I; Luminari S; Vitolo U; Sancetta R; Iannitto E; Trentin L; Stelitano C; Tavera S; Biggi A; Castagnoli A; Versari A; Gregianin M; Pelosi E; Torchio P; Levis A
    Haematologica; 2006 Apr; 91(4):475-81. PubMed ID: 16585014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Positron emission tomography/computed tomography with 18fluoro-deoxyglucose in the detection of local recurrence and distant metastases of pediatric sarcoma.
    Arush MW; Israel O; Postovsky S; Militianu D; Meller I; Zaidman I; Sapir AE; Bar-Shalom R
    Pediatr Blood Cancer; 2007 Dec; 49(7):901-5. PubMed ID: 17252575
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The value of integrated PET-CT images in 2 lymphoma patients with skeletal localisations].
    Geerts MC; Quarles van Ufford HM; Kramer MH; van Waes PF; de Klerk JM
    Ned Tijdschr Geneeskd; 2006 Jan; 150(4):204-9. PubMed ID: 16471237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative study of FDG PET/CT and conventional imaging in the staging of rhabdomyosarcoma.
    Tateishi U; Hosono A; Makimoto A; Nakamoto Y; Kaneta T; Fukuda H; Murakami K; Terauchi T; Suga T; Inoue T; Kim EE
    Ann Nucl Med; 2009 Feb; 23(2):155-61. PubMed ID: 19225939
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of FDG-PET/CT in the management of lymphoma.
    Baba S; Abe K; Isoda T; Maruoka Y; Sasaki M; Honda H
    Ann Nucl Med; 2011 Dec; 25(10):701-16. PubMed ID: 22037934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FDG-PET response-adapted therapy: is 18F-fluorodeoxyglucose positron emission tomography a safe predictor for a change of therapy?
    Hutchings M
    Hematol Oncol Clin North Am; 2014 Feb; 28(1):87-103. PubMed ID: 24287070
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FDG-PET imaging for Hodgkin lymphoma: current use and future applications.
    Kostakoglu L; Evens AM
    Clin Adv Hematol Oncol; 2014 Jan; 12(1):20-35. PubMed ID: 25000313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New developments in staging and follow-up of patients with Hodgkin's lymphoma.
    van Spronsen DJ; Veldhuis GJ
    Neth J Med; 2003 Sep; 61(9):278-84. PubMed ID: 14692440
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PET and PET/CT in management of the lymphomas.
    Podoloff DA; Macapinlac HA
    Radiol Clin North Am; 2007 Jul; 45(4):689-96, vii. PubMed ID: 17706533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical impact of FDG-PET/CT in the planning of radiotherapy for early-stage Hodgkin lymphoma.
    Hutchings M; Loft A; Hansen M; Berthelsen AK; Specht L
    Eur J Haematol; 2007 Mar; 78(3):206-12. PubMed ID: 17253974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of early PET in the management of diffuse large B-cell lymphoma.
    Michallet AS; Trotman J; Tychyj-Pinel C
    Curr Opin Oncol; 2010 Sep; 22(5):414-8. PubMed ID: 20683268
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 2-[18F]fluoro-2-deoxyglucose positron-emission tomography in staging, response evaluation, and treatment planning of lymphomas.
    Specht L
    Semin Radiat Oncol; 2007 Jul; 17(3):190-7. PubMed ID: 17591566
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.